| Literature DB >> 29995231 |
Noriaki Orita1, Tetsuro Shimakami2, Hajime Sunagozaka1, Rika Horii1, Kouki Nio1, Tekeshi Terashima1, Noriho Iida1, Masaaki Kitahara1, Hajime Takatori1, Kazunori Kawaguchi1, Kazuya Kitamura1, Kuniaki Arai1, Taro Yamashita1, Yoshio Sakai1, Tatsuya Yamashita1, Eishiro Mizukoshi1, Masao Honda1, Shuichi Kaneko1.
Abstract
We report three cases of genotype 1b hepatitis C virus (HCV) reinfection after liver transplantation. When antiviral treatment was considered, all three patients had renal dysfunction and had been treated with immunosuppressive agents for a long time; one with tacrolimus (TAC) and the others with cyclosporine A (CyA). Therefore, the possible antiviral regimens among direct-acting antivirals (DAA) were limited and so we treated all three patients with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r). Because ritonavir is known to markedly increase the blood concentration of TAC and CyA through drug-drug interactions, close monitoring of blood concentrations of TAC or CyA and dose adjustments of immunosuppressive agents were needed. Sustained virus response was achieved in all the patients treated, and there were no adverse effects or transplant rejection. OBV/PTV/r might be a useful DAA regimen for patients with genotype 1 HCV reinfection in the setting of renal dysfunction.Entities:
Keywords: Direct-acting antiviral; Hepatitis C virus; Liver transplantation; Ombitasvir/paritaprevir/ritonavir; Reinfection
Mesh：
Substances：
Year: 2018 PMID： 29995231 DOI： 10.1007/s12328-018-0884-y
Source DB: PubMed Journal: Clin J Gastroenterol ISSN： 1865-7265